RecruitingNot ApplicableNCT07665034

Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension

The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension: A Study of Randomized Controlled Trial


Sponsor

Chinese University of Hong Kong

Enrollment

200 participants

Start Date

Oct 15, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Background: Hypertension (HT) is the most common condition worldwide, predisposing to atherosclerotic disease. However, most HT patients have suboptimal BP control despite anti-HT medications. Isometric resistance exercise (IRE) (e.g. wall squat) may improve BP control, characterized by sustained muscle contraction with minimal change in muscle length and joint angle. Most randomized trials of IRE are short duration and their long-term effects on BP and atherosclerotic complications, particularly in the Chinese, remain unknown. Study objectives: (i) To evaluate the impact of IRE on Clinic and Ambulatory BP (AMBP) in Hong Kong Chinese. (ii) To evaluate the impact of IRE on atherogeneisis surrogates (brachial flow-mediated dilation, FMD and carotid intima-media thickness IMT). (iii) To evaluate the impact of IRE on mechanisms of BP reduction, including endothelial function FMD, carotid IMT, inflammatory parameters and arterial wall stiffness (cfPWV). Setting: Randomized samples of 200 HT patients, aged 18-75 years with systolic BP 135-160mHg while on no or stable anti-HT medications. Design: Randomized controlled IRE trial - stratified randomization with randomization block size of 4. 1. 100 patients for wall squat exercise of 14 mins each session (2 mins IRE x 4 sets, 2 mins rest in between), 3 sessions per week, for 1 year, plus advice on healthy diet and lifestyle. 2. 100 control patients (usual care) with advice on diet and healthy lifestyles and simple stretching exercise programme (yoga) for 1 year. All patients will be invited to continue their exercise programme and return for follow up FMD and carotid IMT at 24 weeks and 1 year, and PWV at 24 weeks. Main outcome measures: 1. BP - Clinic BP and Ambulatory BP parameters at baseline, 12 weeks and 24 weeks. (primary outcome) 2. Brachial FMD and carotid IMT at baseline, 24 weeks and 1 year. (primary outcome) 3. Carotid-femoral pulse wave velocity (cf-PWV) at baseline and 24 weeks. 4. Important atherosclerosis risk factor parameters at baseline, 24 weeks and 1 year - including fasting serum glucose, lipid profiles, HgbA1-C, creatinine, hs-CRP, CBP, fibrinogen, and interleukin 6 (IL-6). 5. Safety profiles (if any) including CVS event and hospitalization at 1 year. Expected results: IRE Intervention versus control group, (i) 3mHg more reduction in SBP (Clinic and AMBP). (ii) A group absolute difference in FMD of 1%, and in carotid IMT of 0.06mm between the 2 treatment groups. Implications: IRE as suggested will be beneficial to management of HT, and will be of great importance in health care of this common disorder in both primary and secondary preventions of atherosclerosis diseases.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Squatting Exercise and Stretching (Yoga) Exercise for people with atherosclerosis cardiovascular disease. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSquatting Exercise

14 minutes per session (2 mins x 4 sets, 2 mins rest in between, 3 session per week)

OTHERStretching (Yoga) Exercise

2 mins x 4 sets, 2 mins rest in between, 3 sessions per week


Locations(1)

The Chinese University of Hong Kong, Department of Medicine & Therapeutics

Shatin, Hong Kong

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07665034


Related Trials